Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-26-026601
Filing Date
2026-06-26
Accepted
2026-06-26 17:24:47
Documents
1

Document Format Files

Seq Description Document Type Size
1 DEFA 14A ef20076957_defa14a.htm DEFA14A 42635
  Complete submission text file 0001140361-26-026601.txt   43776
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41740 | Film No.: 261130618
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)